Overview

This is a prospective, single-arm, single-center phase I/II clinical trial evaluating the safety, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) of simultaneous integrated boost accelerated hyperfractionated radiotherapy in patients with high-proliferation non-small cell lung cancer (NSCLC).

Eligibility

Inclusion Criteria:

1. Age ≥ 18 years, male or female;
2. Histologically or cytologically confirmed high-proliferation non-small cell lung cancer (NSCLC);
3. Assessed by a multidisciplinary team (MDT) and planned to receive thoracic radiotherapy (either curative or palliative), regardless of stage.

Exclusion Criteria:

1. Small cell histology;
2. Severe cardiac disease (New York Heart Association \[NYHA\] functional class ≥ III, uncontrolled arrhythmia, or myocardial infarction within the past 6 months);
3. Pregnant or breastfeeding women, or patients of childbearing potential who are unwilling to use effective contraceptive measures;
4. Concurrent participation in other interventional clinical trials;
5. Other conditions deemed by the investigator to make the patient unsuitable for enrollment (e.g., severe mental illness).